Cathie Wood's Ark Invest sold a significant portion of Tempus AI shares following a stock surge driven by positive clinical trial results, indicating profit-taking. Concurrently, Ark continued to reduce its holdings in AMD, a trend observed over recent days, suggesting a strategic reallocation or reduced conviction in the chipmaker.
Cathie Wood's Ark Invest made notable portfolio adjustments. The sale of $15.6 million in Tempus AI (TEM) shares comes after a significant price surge, likely representing profit-taking following a successful clinical trial. This could signal Ark believes the stock has reached a near-term peak, potentially putting downward pressure on TEM in the short term. The continued selling of AMD shares, totaling $3.4 million on Tuesday and $4.1 million on Monday, suggests a broader strategic shift or reduced conviction in the chipmaker, despite its AI infrastructure expansion plans. This ongoing divestment could create headwinds for AMD's stock. For traders, this indicates Ark's active management and willingness to trim positions in high-flying stocks or those where conviction may be waning, offering potential short-term trading opportunities based on these shifts.